BRIEF-Allarity Therapeutics Reports Key Progress In Phase 2 Stenoparib Trial

Reuters11-18

BRIEF-Allarity <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Key Progress In Phase 2 Stenoparib Trial

Nov 18 (Reuters) - Allarity Therapeutics Inc ALLR.O:

ALLARITY THERAPEUTICS REPORTS KEY PROGRESS IN PHASE 2 STENOPARIB TRIAL AND STRATEGIC CORPORATE ADVANCEMENTS
ALLARITY THERAPEUTICS INC - MAINTAINS CASH BALANCE OF $18.5 MILLION
ALLARITY THERAPEUTICS INC - TWO PATIENTS EXCEED 14 MONTHS ON TREATMENT IN PHASE 2 TRIAL

Source text: ID:nGNXVGJSz

Further company coverage: ALLR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484622101?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484622101","market":"us","top_or_hot":-1,"title":"BRIEF-Allarity Therapeutics Reports Key Progress In Phase 2 Stenoparib Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Allarity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Key Progress In Phase 2 Stenoparib Trial</title></head><body><p><span>Nov 18 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/ALLR\">Allarity Therapeutics Inc</a> <span>ALLR.O</span>:</p><ul><li><p>ALLARITY THERAPEUTICS REPORTS KEY PROGRESS IN PHASE 2 STENOPARIB TRIAL AND STRATEGIC CORPORATE ADVANCEMENTS</p></li><li><p>ALLARITY THERAPEUTICS INC - MAINTAINS CASH BALANCE OF $18.5 MILLION</p></li><li><p>ALLARITY THERAPEUTICS INC - TWO PATIENTS EXCEED 14 MONTHS ON TREATMENT IN PHASE 2 TRIAL</p></li></ul><p>Source text: <span>ID:nGNXVGJSz</span></p><p>Further company coverage: <span>ALLR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Allarity Therapeutics Reports Key Progress In Phase 2 Stenoparib Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Allarity Therapeutics Reports Key Progress In Phase 2 Stenoparib Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-18 21:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA6QX6FX:1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BRIEF-Allarity Therapeutics Reports Key Progress In Phase 2 Stenoparib TrialNov 18 (Reuters) - Allarity Therapeutics Inc ALLR.O:ALLARITY THERAPEUTICS REPORTS KEY PROGRESS IN PHASE 2 STENOPARIB TRIAL ...</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA6QX6FX:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nTUA6QX6FX:1","article_id":"2484622101","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484622101","pubTimestamp":1731935589,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Allarity Therapeutics Reports Key Progress In Phase 2 Stenoparib TrialNov 18 (Reuters) - Allarity Therapeutics Inc ALLR.O:ALLARITY THERAPEUTICS REPORTS KEY PROGRESS IN PHASE 2 STENOPARIB TRIAL A","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ALLR":"Allarity Therapeutics Inc"},"translate_title":"简报-Allarity Therapeutics报告stenoparib 2期试验的关键进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLR":0.9},"content_text":"BRIEF-Allarity Therapeutics Reports Key Progress In Phase 2 Stenoparib TrialNov 18 (Reuters) - Allarity Therapeutics Inc ALLR.O:ALLARITY THERAPEUTICS REPORTS KEY PROGRESS IN PHASE 2 STENOPARIB TRIAL AND STRATEGIC CORPORATE ADVANCEMENTSALLARITY THERAPEUTICS INC - MAINTAINS CASH BALANCE OF $18.5 MILLIONALLARITY THERAPEUTICS INC - TWO PATIENTS EXCEED 14 MONTHS ON TREATMENT IN PHASE 2 TRIALSource text: ID:nGNXVGJSzFurther company coverage: ALLR.O ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484622101"}